Avidity Biosciences to Participate in Upcoming Investor Conference
Thursday, October 16, 2025 1 min read
Key Takeaway: Avidity Biosciences, Inc. announced its participation in an upcoming investor conference, where management will engage in a panel discussion. The company focuses on developing Antibody Oligonucleotide Conjugates (AOCs™) aimed at treating rare muscle diseases and advancing its pipeline in cardiology and immunology. A live webcast of the event will be available on their website.
Price reaction · baseline $51.025 (2025-10-16T13:59:00.000Z) · hit during market hours · clean, no other RNA news in the window
day 0 close · peak
-4.4%
Market Sentiment Analysis
POSITIVE FACTORS
Avidity is participating in an investor conference, showcasing engagement.
The company is pioneering a new class of RNA therapeutics.
Avidity's AOC platform is leading clinical development for rare muscle diseases.
Full Press Release Details
SAN DIEGO,Oct. 16, 2025/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a panel discussion at the following investor conference:
About AvidityAvidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visitwww.aviditybiosciences.comand engage with us onLinkedInandX.